search
Back to results

Stress-induced Sleep Deficits and a Complementary Therapy (Sleep-Aid)

Primary Purpose

Insomnia Due to Anxiety and Fear

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
DHM
Placebo
Sponsored by
University of Southern California
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Insomnia Due to Anxiety and Fear

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy subjects were recruited in Chengdu and Beijing (city) in China,
  • Able and willing to sign informed consent,
  • Between 18 -60 years old at time of consent,
  • No alcohol, drug, and smoking,
  • Not using sleep medication(s) or other psychiatric medications.

Exclusion Criteria:

  • Pregnant or Breastfeeding women,
  • Currently taking any medications for sleep,
  • Reported naps > 3 times per week
  • History of sleep apnea,
  • Current alcohol, drug, and smoking

Sites / Locations

  • Furise Group Co

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

DHM group

Control group

Arm Description

This arm is to evaluate DHM effects on the intervention of stress-induced insomnia during the pandemic. DHM granular preparation contains DHM 200 mg plus same excipients as placebo. The 244 participants were taken DHM granular preparation, which was dissolved in ~100 ml water for oral administration, once daily for 20 days.

The placebo contained excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g

Outcomes

Primary Outcome Measures

Effect of DHM on sleep duration
Changes in hours of sleep reported as the difference between self-reported hours of sleep before and after DHM or placebo.
Effect of DHM on stress levels
Changes in stress levels reported as the difference between self-reported stress levels before and after DHM or placebo. Stress levels were scaled from 0 to 10, with 10 being the highest stress level.
Effect of DHM on cellphone time
Changes in hours spent on cellphone reported as the difference between self-reported cellphone usage before and after DHM or placebo.
Effect of DHM on feelings after waking up
Changes in negative feelings after waking up, reported as the difference between the self-reported negative feelings before and after DHM or placebo. In the survey, "feelings after waking up" included negative feelings such as tense, lack of motivation, and irritable/angry. To quantify these feelings, a 'Yes' counted as -1 point, a 'No' counted as 0 points, and a 'Not sure' counted as -0.5 points. The sum of these scores were calculated as the total negative feeling after waking up. Lower score (more negative) indicated worse feelings.

Secondary Outcome Measures

Full Information

First Posted
February 11, 2022
Last Updated
January 3, 2023
Sponsor
University of Southern California
Collaborators
University of California, Los Angeles
search

1. Study Identification

Unique Protocol Identification Number
NCT05280561
Brief Title
Stress-induced Sleep Deficits and a Complementary Therapy
Acronym
Sleep-Aid
Official Title
Stress-, Anxiety-, and Cellphone Use-induced Sleep Deficits and Psychological Conditions During the Pandemic and a Potential Complementary Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
July 25, 2021 (Actual)
Primary Completion Date
October 31, 2022 (Actual)
Study Completion Date
November 3, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Southern California
Collaborators
University of California, Los Angeles

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The COVID-19 pandemic and social isolation order induced stress/anxiety as well as cellphone dependence. As a result, sleep disruption and mental distress became major health concerns. Gamma-aminobutyric acid type-A receptor (GABAAR) is one of the key players in modulating sleep. Dihydromyricetin (DHM), an herbal compound, plays a role in GABAAR modulation and mitigating anxiety. The investigators' partner in China obtained 288 participants who completed the online survey to gain insight into how stress/anxiety and time spent on cellphones affected sleep and mood. The participants were then enrolled in a randomized placebo-controlled double-blind study to assess the effects of DHM on sleep and improvement on stress/anxiety and cellphone using time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia Due to Anxiety and Fear

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
288 subjects were recruited for the study. The sample size was based on a prior power analyses using G-Power 3, for a Mixed Model Repeated Measures Analysis of Variance (MMRMA) design, assuming a statistical power of 0.8, moderate effects of the DHM effects on sleep outcomes, and hypothesis tests conducted at a probability value of .05.
Masking
Participant
Allocation
Randomized
Enrollment
288 (Actual)

8. Arms, Groups, and Interventions

Arm Title
DHM group
Arm Type
Experimental
Arm Description
This arm is to evaluate DHM effects on the intervention of stress-induced insomnia during the pandemic. DHM granular preparation contains DHM 200 mg plus same excipients as placebo. The 244 participants were taken DHM granular preparation, which was dissolved in ~100 ml water for oral administration, once daily for 20 days.
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
The placebo contained excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
Intervention Type
Dietary Supplement
Intervention Name(s)
DHM
Intervention Description
DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
Primary Outcome Measure Information:
Title
Effect of DHM on sleep duration
Description
Changes in hours of sleep reported as the difference between self-reported hours of sleep before and after DHM or placebo.
Time Frame
20 days
Title
Effect of DHM on stress levels
Description
Changes in stress levels reported as the difference between self-reported stress levels before and after DHM or placebo. Stress levels were scaled from 0 to 10, with 10 being the highest stress level.
Time Frame
20 days
Title
Effect of DHM on cellphone time
Description
Changes in hours spent on cellphone reported as the difference between self-reported cellphone usage before and after DHM or placebo.
Time Frame
20 days
Title
Effect of DHM on feelings after waking up
Description
Changes in negative feelings after waking up, reported as the difference between the self-reported negative feelings before and after DHM or placebo. In the survey, "feelings after waking up" included negative feelings such as tense, lack of motivation, and irritable/angry. To quantify these feelings, a 'Yes' counted as -1 point, a 'No' counted as 0 points, and a 'Not sure' counted as -0.5 points. The sum of these scores were calculated as the total negative feeling after waking up. Lower score (more negative) indicated worse feelings.
Time Frame
20 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy subjects were recruited in Chengdu and Beijing (city) in China, Able and willing to sign informed consent, Between 18 -60 years old at time of consent, No alcohol, drug, and smoking, Not using sleep medication(s) or other psychiatric medications. Exclusion Criteria: Pregnant or Breastfeeding women, Currently taking any medications for sleep, Reported naps > 3 times per week History of sleep apnea, Current alcohol, drug, and smoking
Facility Information:
Facility Name
Furise Group Co
City
Chengdu
State/Province
Sichuan
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
22219299
Citation
Shen Y, Lindemeyer AK, Gonzalez C, Shao XM, Spigelman I, Olsen RW, Liang J. Dihydromyricetin as a novel anti-alcohol intoxication medication. J Neurosci. 2012 Jan 4;32(1):390-401. doi: 10.1523/JNEUROSCI.4639-11.2012.
Results Reference
result
PubMed Identifier
24728903
Citation
Liang J, Lopez-Valdes HE, Martinez-Coria H, Lindemeyer AK, Shen Y, Shao XM, Olsen RW. Dihydromyricetin ameliorates behavioral deficits and reverses neuropathology of transgenic mouse models of Alzheimer's disease. Neurochem Res. 2014 Jun;39(6):1171-81. doi: 10.1007/s11064-014-1304-4. Epub 2014 Apr 13. Erratum In: Neurochem Res. 2014 Jul;39(7):1403.
Results Reference
result
PubMed Identifier
32742262
Citation
Silva J, Shao AS, Shen Y, Davies DL, Olsen RW, Holschneider DP, Shao XM, Liang J. Modulation of Hippocampal GABAergic Neurotransmission and Gephyrin Levels by Dihydromyricetin Improves Anxiety. Front Pharmacol. 2020 Jul 9;11:1008. doi: 10.3389/fphar.2020.01008. eCollection 2020.
Results Reference
result

Learn more about this trial

Stress-induced Sleep Deficits and a Complementary Therapy

We'll reach out to this number within 24 hrs